Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | MLNR | O43193 | 11/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396312 | 1.00 | LMNA (0.51) | LMNAALDH1A1GBA1HRH3HRH4 | |
| SCHEMBL20803929 | 0.83 | MLNR (0.47) | LMNAALDH1A1HRH3HRH4MLNR | |
| SCHEMBL5059571 | 0.82 | MLNR (0.56) | HRH3HRH4MLNRCYP3A4SIGMAR1 | |
| SCHEMBL5059568 | 0.82 | MLNR (0.56) | HRH3HRH4MLNRCYP3A4SIGMAR1 | |
| SCHEMBL12499778 | 0.82 | SIGMAR1 (0.48) | ALDH1A1HRH3HRH4MLNRCYP3A4 | |
| SCHEMBL3522693 | 0.81 | FUCA1 (0.55) | LMNAALDH1A1GBA1MLNRCYP3A4 | |
| SCHEMBL3522692 | 0.81 | FUCA1 (0.55) | LMNAALDH1A1GBA1MLNRCYP3A4 | |
| SCHEMBL3324661 | 0.81 | FUCA1 (0.55) | LMNAALDH1A1GBA1MLNRCYP3A4 | |
| SCHEMBL4279682 | 0.81 | FUCA1 (0.55) | LMNAALDH1A1GBA1MLNRCYP3A4 | |
| SCHEMBL15651766 | 0.81 | LMNA (0.51) | LMNAALDH1A1MLNRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | LMNA 3429/4885ALDH1A1 1389/4885GBA1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.